31/08/2015 04:52:37 Free Membership Login

Neurocrine Biosciences News (NASDAQ:NBIX)

DateTimeSource
Headline
08/13/20158:00AMPRNUSNeurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study
Neurocrine Announces Completion of Enrollment into Kinect 3 Tardive Dyskinesia Study Pivotal Phase III Study Evaluating NBI-98854 PR Newswire SAN DIEGO, Aug. 13, 2015 SAN DIEGO, Aug. 13, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has recently completed subject randomization... More...>>
08/11/20159:35AMPRNUSTechnical Updates on Healthcare Sector Equities -- Brookdale Senior Living, Envision Healthcare Holdings, BioScrip, Perrigo a...
Technical Updates on Healthcare Sector Equities -- Brookdale Senior Living, Envision Healthcare Holdings, BioScrip, Perrigo and Neurocrine Biosciences PR Newswire NEW YORK, August 11, 2015 NEW YORK, August 11, 2015 /PRNewswire/ -- Equity Research Institute has initiated coverage on the following equities: Brookdale Senior... More...>>
07/29/20154:01PMPRNUSNeurocrine Biosciences Reports Second Quarter 2015 Results
Neurocrine Biosciences Reports Second Quarter 2015 Results Patient recruitment nears completion for Kinect 3 Phase III Study Chief Commercial Officer and Vice President of Medical Affairs join the Company Elagolix twelve month endometriosis efficacy and safety data consistent with previously reported six month data PR... More...>>
07/22/20151:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2015 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2015 Results Conference Call and Webcast Scheduled For Wednesday, July 29, 2015 PR Newswire SAN DIEGO, July 22, 2015 SAN DIEGO, July 22, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company... More...>>
06/08/20154:27PMPRNUSNeurocrine Biosciences Provides Update on NBI-77860 Program for Congenital Adrenal Hyperplasia
Neurocrine Biosciences Provides Update on NBI-77860 Program for Congenital Adrenal Hyperplasia Based on Preclinical Observations, Two Clinical Studies of NBI-77860 Halted by the Company Prior to Patient Enrollment PR Newswire SAN DIEGO, June 8, 2015 SAN DIEGO, June 8, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc... More...>>
06/02/20158:00AMPRNUSNeurocrine Biosciences, Inc. Announces Appointment of Eric Benevich as Chief Commercial Officer
Neurocrine Biosciences, Inc. Announces Appointment of Eric Benevich as Chief Commercial Officer PR Newswire SAN DIEGO, June 2, 2015 SAN DIEGO, June 2, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Eric Benevich has joined the company as Chief Commercial Officer. "We are very pleased... More...>>
05/27/20153:54PMPRNUSNeurocrine Biosciences to Present at the Jefferies 2015 Healthcare Conference
Neurocrine Biosciences to Present at the Jefferies 2015 Healthcare Conference Live Audio Webcast Will be on June 2, 2015 PR Newswire SAN DIEGO, May 27, 2015 SAN DIEGO, May 27, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer of Neurocrine... More...>>
05/12/20154:01PMPRNUSNeurocrine Biosciences to Host Analyst and Investor Day in New York City on May 21, 2015
Neurocrine Biosciences to Host Analyst and Investor Day in New York City on May 21, 2015 Live Audio Webcast Will be on May 21, 2015 PR Newswire SAN DIEGO, May 12, 2015 SAN DIEGO, May 12, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will host an Analyst and Investor Day at the... More...>>
05/08/20151:00PMPRNUSNeurocrine Biosciences to Present at the Bank of America Merrill Lynch 2015 Health Care Conference
Neurocrine Biosciences to Present at the Bank of America Merrill Lynch 2015 Health Care Conference Live Audio Webcast Will be on May 14, 2015 PR Newswire SAN DIEGO, May 8, 2015 SAN DIEGO, May 8, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
05/04/20154:01PMPRNUSNeurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs
Neurocrine Biosciences, Inc. Announces Appointment of Dr. Bill Aurora as Vice President, Medical Affairs PR Newswire SAN DIEGO, May 4, 2015 SAN DIEGO, May 4, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) today announced that Dr. Bill Aurora has joined the company as Vice President, Medical Affairs... More...>>
04/30/20151:00PMPRNUSNeurocrine Biosciences to Present at the Deutsche Bank 40th Annual Health Care Conference
Neurocrine Biosciences to Present at the Deutsche Bank 40th Annual Health Care Conference Live Audio Webcast Will be on May 7, 2015 PR Newswire SAN DIEGO, April 30, 2015 SAN DIEGO, April 30, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
04/30/20157:00AMPRNUSNeurocrine Biosciences Reports First Quarter 2015 Results
Neurocrine Biosciences Reports First Quarter 2015 Results - Successful Secondary Offering-Company has over $500 Million Available to Fund Pipeline- -Positive Top-Line Efficacy from First Elagolix Endometriosis Phase III Study- -AbbVie Completes Recruiting for Elagolix Uterine Fibroids Phase IIB Study- -NBI-98854 Partnered... More...>>
04/28/20158:20PMARNNeurocrine Biosciences Lifted to Strong-Buy at Vetr Inc. (NBIX)
http://tickerreport.com/banking-finance/479970/neurocrine-biosciences-lifted-to-strong-buy-at-vetr-inc-nbix/?utm_source=ADVFN&utm_medium=banner&utm_campaign=ADVFN More...>>
04/23/20151:00PMPRNUSNeurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results
Neurocrine Biosciences Announces Conference Call and Webcast to Report First Quarter 2015 Results Conference Call and Webcast Scheduled For Thursday, April 30, 2015 PR Newswire SAN DIEGO, April 23, 2015 SAN DIEGO, April 23, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the Company... More...>>
03/31/201510:00PMPRNUSNeurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854...
Neurocrine Biosciences and Mitsubishi Tanabe Pharma Announce Agreement to Develop and Commercialize VMAT2 Inhibitor NBI-98854 for Movement Disorders in Japan and Other Select Asian Markets PR Newswire SAN DIEGO, March 31, 2015 SAN DIEGO, March 31, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced... More...>>
03/03/20151:00PMPRNUSNeurocrine Biosciences to Present at the Barclays Global Healthcare Conference Live Audio Webcast Will be on March 10, 2015
Neurocrine Biosciences to Present at the Barclays Global Healthcare Conference Live Audio Webcast Will be on March 10, 2015 PR Newswire SAN DIEGO, March 3, 2015 SAN DIEGO, March 3, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer... More...>>
02/24/20151:00PMPRNUSNeurocrine Biosciences to Present at Cowen and Company's 35th Annual Health Care Conference
Neurocrine Biosciences to Present at Cowen and Company's 35th Annual Health Care Conference Live Audio Webcast Will be on March 3, 2015 PR Newswire SAN DIEGO, Feb. 24, 2015 SAN DIEGO, Feb. 24, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>>
02/20/20157:00AMPRNUSNeurocrine Biosciences, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares
Neurocrine Biosciences, Inc. Announces Exercise in Full of Underwriters' Option to Purchase Additional Shares PR Newswire SAN DIEGO, Feb. 20, 2015 SAN DIEGO, Feb. 20, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that the underwriters of its previously announced public offering have exercised... More...>>
02/19/20157:00AMPRNUSNeurocrine Biosciences, Inc. Prices Public Offering of Common Stock
Neurocrine Biosciences, Inc. Prices Public Offering of Common Stock PR Newswire SAN DIEGO, Feb. 19, 2015 SAN DIEGO, Feb. 19, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the pricing of its underwritten public offering of 6,944,000 shares of its common stock at a price to the public of... More...>>
02/17/20154:08PMPRNUSNeurocrine Biosciences, Inc. Announces Proposed Public Offering of $225 Million of Common Stock
Neurocrine Biosciences, Inc. Announces Proposed Public Offering of $225 Million of Common Stock PR Newswire SAN DIEGO, Feb. 17, 2015 SAN DIEGO, Feb. 17, 2015 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced that it has commenced an underwritten public offering of shares of its common stock to... More...>>


Your Recent History
LSE
GKP
Gulf Keyst..
LSE
QPP
Quindell
FTSE
UKX
FTSE 100
LSE
IOF
Iofina
FX
GBPUSD
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE and AMEX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

1 site:2 us nasdaq nbix150831 04:52